FDA issues alert about HIV drug Prezista

Mar 24, 2008

The U.S. Food and Drug Administration has issued an alert concerning reports of liver injury in patients taking Prezista.

The FDA said Prezista (darunavir), an anti-retroviral drug used to treat for the human immunodeficiency virus HIV, is suspected of contributing to several hepatic events, including liver failure, destruction of liver tissue, cirrhosis, hepatitis and jaundice.

Healthcare professionals were advised to conduct appropriate laboratory testing prior to and after starting patients on Prezista and to be alert for symptoms of hepatotoxicity, including unexplained fatigue, anorexia, nausea, jaundice, dark urine and liver tenderness.

Patients with chronic hepatitis B or C or those who have pretreatment elevations of liver function tests should be monitored more frequently.

The FDA said it worked with the drug's manufacturer -- Tibotec Therapeutics Inc. of Bridgewater, N.J. -- to include the new hepatotoxicity information on the drug's label.

Copyright 2008 by United Press International

Explore further: Achieving a world without AIDS: Scale must give way to focus, details

add to favorites email to friend print save as pdf

Related Stories

Davos elites warned about catastrophic cyberattacks

15 hours ago

Attacks on power plants, telecommunications and financial systems, even turning all of Los Angeles' traffic lights green: Davos elites were warned Saturday of the terrifying possibilities of modern cyber ...

Recommended for you

AIDS crisis brewing in Crimea and east Ukraine says UN

Jan 21, 2015

A lethal health crisis is brewing in Russian-annexed Crimea and war-torn eastern Ukraine, where injecting drug users have lost access to therapy to wean them off heroin, the UN's AIDS envoy said Wednesday.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.